SOURCE: AtheroNova Inc.

AtheroNova Inc.

June 20, 2011 09:20 ET

AtheroNova Inc. Names Ephraim Sehayek, M.D. of the Cleveland Clinic to Scientific Advisory Board

IRVINE, CA--(Marketwire - Jun 20, 2011) - AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that Ephraim Sehayek, M.D. of the Cleveland Clinic has been named to the Company's Scientific Advisory Board. Dr. Sehayek is Assistant Staff at the Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, and Assistant Professor of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

"AtheroNova's development of bile compounds for the regression of atherosclerotic plaque has great potential to create significant new therapeutic options for the treatment of large patient populations," said Dr. Sehayek. "The Company's core research and development focus on lipids and plaque regression represents a promising approach and I look forward to working with the Company as they progress to upcoming human trials."

"Dr. Sehayek is one of the foremost researchers in the study of atherosclerosis, lipids, genomics and reverse cholesterol transport," stated Thomas W. Gardner, CEO of AtheroNova. "His encyclopedic knowledge of the field and ongoing research focus at one of the nation's premier research institutes will provide valuable insights to help accelerate our clinical development program. We are honored to welcome him to our Scientific Advisory Board."

Dr. Sehayek completed his M.D. at the University of Tel Aviv, Sackler School of Medicine. He specialized in internal medicine at the Sheba Medical Center, Ramat Gan, Israel, and was formally trained in Endocrinology and Metabolism at the Hadassah Medical Center in Jerusalem. Dr. Sehayek studied laboratory-based human lipoprotein metabolism under the tutelage of Shlomo Eisenberg at the Lipid Research Center in Jerusalem. In 1996 Dr. Sehayek was awarded the Lipper Clinical Scholar Fellowship and joined the Laboratory of Biochemical Genetics and Metabolism at the Rockefeller University, New York, where he worked with Jan Breslow on mouse and human genetics of lipid metabolism. He joined the Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic in June of 2008.

Dr. Sehayek is the author of over fifty peer-reviewed research publications. His recent research focuses on lipids, cholesterol, reverse cholesterol transport, atherosclerosis, and genome wide association studies for the development of new therapies.

About AtheroNova

AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis, obesity and lipomas.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding the value of Dr. Sehayek's appointment to AtheroNova's Scientific Advisory Board, and the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Company Contact:

    Thomas Gardner
    Chief Executive Officer
    (949) 476-1100

    Mark Selawski
    Chief Financial Officer
    (949) 476-1100

    Investor Contact:

    Leon Hamerling
    Investor Media Group
    (877) 725-2500